These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17220044)

  • 41. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pneumococcal polysaccharide vaccines do not protect the elderly from pneumococcal infections.
    Lipsky BA; Hirschmann JV
    Neth J Med; 2004 Feb; 62(2):33-5. PubMed ID: 15127828
    [No Abstract]   [Full Text] [Related]  

  • 43. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
    Scott DA; Komjathy SF; Hu BT; Baker S; Supan LA; Monahan CA; Gruber W; Siber GR; Lockhart SP
    Vaccine; 2007 Aug; 25(33):6164-6. PubMed ID: 17629361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Considerations on pediatric pneumococcal infection in Navarra].
    Bernaola E; Herranz M; Clerigué N; Torroba L; Gil F; Gil-Setas A
    Rev Esp Quimioter; 2007 Mar; 20(1):143-9. PubMed ID: 17530048
    [No Abstract]   [Full Text] [Related]  

  • 45. Interpreting vaccine efficacy.
    Greenwood B
    Clin Infect Dis; 2005 May; 40(10):1519-20. PubMed ID: 15844076
    [No Abstract]   [Full Text] [Related]  

  • 46. [111th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: 4. Health care for the elderly and vaccination: Current situation of pneumococcal vaccines and pneumococcal diseases].
    Oishi K
    Nihon Naika Gakkai Zasshi; 2014 Sep; 103(9):2247-51. PubMed ID: 27522786
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.
    Leach AJ; Morris PS; Mackenzie G; McDonnell J; Balloch A; Carapetis J; Tang M
    Vaccine; 2008 Jul; 26(31):3885-91. PubMed ID: 18562052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Might Streptococcus pneumoniae urinary antigen test be positive because of pneumococcal vaccine?
    Priner M; Cornillon C; Forestier D; Valero S; Paccalin M
    J Am Geriatr Soc; 2008 Jan; 56(1):170-1. PubMed ID: 18184209
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pneumococcal polysaccharide vaccine].
    Van Laethem Y
    Rev Med Brux; 2004 Sep; 25(4):A227-8. PubMed ID: 15516046
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden.
    Spindler C; Hedlund J; Jasir A; Normark BH; Ortqvist A
    Vaccine; 2008 Oct; 26(43):5541-6. PubMed ID: 18602961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The shifting dynamics of pneumococcal invasive disease after the introduction of the pneumococcal 7-valent conjugated vaccine: toward the new pneumococcal conjugated vaccines.
    Greenberg D
    Clin Infect Dis; 2009 Jul; 49(2):213-5. PubMed ID: 19508164
    [No Abstract]   [Full Text] [Related]  

  • 53. [The importance of pneumococcal vaccination - a clinician's view].
    Havlík J
    Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):30, 32-5. PubMed ID: 18327738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
    Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
    Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccines in the era of genomics: the pneumococcal challenge.
    Barocchi MA; Censini S; Rappuoli R
    Vaccine; 2007 Apr; 25(16):2963-73. PubMed ID: 17324490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe Inflammatory Response in Myelodysplastic Syndrome and Trisomy 8 Following 23-Valent Polysaccharide Pneumococcal Vaccine Administration.
    Fujikawa H; Miyazato Y; Ebisuda K; Saito M
    Turk J Haematol; 2021 Feb; 38(1):92-94. PubMed ID: 33635039
    [No Abstract]   [Full Text] [Related]  

  • 57. Prevenar vaccination: review of the global data, 2006.
    Center KJ
    Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological responses to pneumococcal vaccine in frail older people.
    Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
    Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.